A major goal for hepatitis C virus (HCV) vaccine development is to elicit broadly neutralizing antibodies (bNAbs) against the E1E2 glycoprotein complex located on the viral surface. Inducing HCV bNAbs requires engagement of their germline B cell precursors. HCV glycoproteins usually do not bind and activate inferred ge...
Fabian Mulder, F. Cannac, Joan Capella-Pujol et al.· bioRxiv· 0 citations
Hepatitis C virus (HCV) affects 47 million people and causes 239,000 deaths annually, yet no vaccine is on the horizon. Generating a stable native-like mimic of the envelope complex E1E2, the only target for known neutralizing antibodies, is an important aim for HCV vaccine development. Starting from a recombinant E1E2...
Joan Capella-Pujol, Fabian Mulder, F. Cannac et al.· Nature Communications· 1 citation
A systematic comparison is made between PIEZO1 reconstituted in detergent micelles and in cell membrane–derived nanodiscs, establishing native membranes as critical determinants for mechanotransduction.
Sanjai Karanth, Alessandro Nicoli, F. Cannac et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.